Klinische Studie

M23-696 – A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing theSafety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to SevereAtopic Dermatitis (Level-Up)